tbuckley/cabot-search huggingface dataset:
Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade®, ICL670) and Deferoxamine (DFO).
Authors: E. Vichinsky, R. Fischer, Z. Pakbaz, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B.U. Mueller, L. Coïc, G. Forni, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, I. Gathmann, D. Alberti, P. Marks
Journal: Blood (2005)
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
Authors: Philip D. Poorvu, Shari I. Gelber, Shoshana M. Rosenberg, Kathryn J. Ruddy, Rulla M. Tamimi, Laura C. Collins, Jeffrey Peppercorn, Lidia Schapira, Virginia F. Borges, Steven E. Come, Ellen Warner, Debbie M. Jakubowski, Christy Russell, Eric P. Winer, Ann H. Partridge
Journal: Journal of Clinical Oncology (2019)

The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer and is used to inform recommendations for chemotherapy. Women ≤ 40 years of age represent a minority of patients studied using gene expression profiles.The Young Women's Breast Cancer Study is a prospective cohort of women diagnosed with breast cancer at age ≤ 40 years and enrolled patients between 2006 and 2016 (N = 1,302). We identified patients with stage I-III ER+/HER2- breast cancer. The RS assay was performed on banked specimens for patients who had not been tested clinically. Distant recurrence-free survival (DRFS) was assessed by TAILORx and traditional RS risk groups among patients with axillary node-negative (N0) and limited node-positive (N1) breast cancer.Among eligible women (N = 577), 189 (33%) had undergone RS testing, and 320 (56%) had banked specimens sufficient for testing. Median follow-up was 6.0 years. Median age at diagnosis was 37.2 years; 300 of 509 patients (59%) had N0 breast cancer, of whom 195 (65%) had an RS of 11-25 and fewer than half (86 of 195; 44%) received chemotherapy. Six-year DRFS rates were 94.4% and 92.3% (RS < 11), 96.9% and 85.2% (RS 11-25), and 85.1% and 71.3% (RS ≥ 26) among women with N0 and N1 disease, respectively.The RS assay is prognostic among young women with node-negative and limited node-positive breast cancer, representing a valuable tool for risk stratification. Disease outcomes with a median follow-up of 6 years among young women with N0 disease and an RS of 0-25, a minority of whom received chemotherapy, and node-positive disease with an RS < 11 were very good, whereas those with N0 disease and an RS ≥ 26 or N1 disease with an RS ≥ 11 experienced substantial risk of early distant recurrence.
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Authors: Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y. C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers
Journal: Journal for ImmunoTherapy of Cancer (2019)

Abstract.The original article can be found online at 10.1186/s40425-018-0420-0 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial
Authors: Xinfeng Liu, Qiliang Dai, Ruidong Ye, Wenjie Zi, Yuxiu Liu, Huaiming Wang, Wusheng Zhu, Minmin Ma, Qin Yin, Min Li, Xinying Fan, Wen Sun, Yunfei Han, Qiushi Lv, Rui Liu, Dong Yang, Zhonghua Shi, Dequan Zheng, Xiaorong Deng, Yue Wan, Zhen Wang, Yu Geng, Xingyu Chen, Zhiming Zhou, Geng Liao, Ping Jin, Yumin Liu, Xintong Liu, Meng Zhang, Feng Zhou, Hongchao Shi, Yunfeng Zhang, Fuqiang Guo, Congguo Yin, Guozhong Niu, Mei Zhang, Xueli Cai, Qiyi Zhu, Zhonglun Chen, Yingchun Liang, Bing Li, Min Lin, Wei Wang, Haowen Xu, Xinmin Fu, Wenhua Liu, Xiguang Tian, Zili Gong, Haicun Shi, Chuanming Wang, Penghua Lv, Zhonghai Tao, Liangfu Zhu, Shiquan Yang, Wei Hu, Pingzhou Jiang, David S Liebeskind, Vitor M Pereira, Thomas Leung, Bernard Yan, Stephen Davis, Gelin Xu, Raul G Nogueira, Xinfeng Liu, Gelin Xu, Wusheng Zhu, Minmin Ma, Yunyun Xiong, Wenjie Zi, Qiliang Dai, Huaiming Wang, Ruidong Ye, Yuxiu Liu, Zhonghua Shi, Dequan Zheng, Xiaorong Deng, Yue Wan, Zhen Wang, Yu Geng, Zongjie Shi, Weihong Zheng, Xingyu Chen, Zhiming Zhou, Xianjun Huang, Geng Liao, Ping Jin, Yong Liu, Yumin Liu, Huagang Li, Xintong Liu, Meng Zhang, Feng Zhou, Hongchao Shi, Kaifu Ke, Yunfeng Zhang, Fuqiang Guo, Shu Yang, Congguo Yin, Guozhong Niu, Mei Zhang, Xueli Cai, Qiyi Zhu, Zhonglun Chen, Yingchun Liang, Bing Li, Min Lin, Hang Lin, Wei Wang, Haowen Xu, Xinmin Fu, Wei Dan, Wenhua Liu, Xiguang Tian, Lin Chen, Zili Gong, Haicun Shi, Chuanming Wang, Penghua Lv, Zhonghai Tao, Liangqun Rong, Liangfu Zhu, Shuiping Wang, Shiquan Yang, Wei Hu, Pingzhou Jiang, Jin Fan, Chengming Xing, Haifeng Li, Weiming Yang, Changqing Wang, Yong Zhang, Penghua Lv, Xiaobo Li, Vitor Pereira, Bernard Yan, David Liebeskind, Thomas Leung, Stephen Davis, Raul Nogueira
Journal: The Lancet Neurology (2019)
Inclusion of All Patients Admitted for Trauma in Trauma Registries—Reply
Authors: Craig D. Newgard, Eileen M. Bulger
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Impaired T-Lymphocyte Subpopulations and Deranged Profile of Immunologic Activation in Patients with Gaucher Disease Type I
Authors: Argiris S Symeonidis, George Theodorou, Constantina Repa, Theodore Marinakis, Panayiotis Tsaftaridis, Alexandra Kouraklis, Marina Karakantza, Nicholas Zoumbos
Journal: Blood (2008)
Proteomic analysis of decellularized pancreatic matrix identifies collagen V as a critical regulator for islet organogenesis from human pluripotent stem cells
Authors: Huanjing Bi, Kaiming Ye, Sha Jin
Journal: Biomaterials (2019)

In pancreatic tissue engineering, generating human pancreatic islet organoids from stem cells has been challenging due mainly to a poor understanding of niches required for multicellular tissue self-assembly in vitro. In this study, we aimed to identify bioactive, chemically defined niches from natural, biological materials for islet development in vitro. We investigated the proteomics of decellularized rat pancreatic extracellular matrix (dpECM) hydrogel using advanced bioinformatics analysis, and identified that type V collagen (ColV) is constantly and abundantly present in dpECM hydrogel. Niches provided to human pluripotent stem cells (iPSCs) by presenting ColV in matrix coating substrates permitted stem cells progression into islet-like organoids that consist of all major pancreatic endocrine cell types, i.e. α, β, δ, and pancreatic polypeptide cells. In the presence of ColV niches, gene expressions of all key pancreatic transcription factors and major hormone genes significantly increased in iPSC-derived organoids. Most importantly, ColV-containing microenvironment resulted in enhanced glucose responsive secretions of both insulin and glucagon hormone from organoids. The study demonstrates that ColV is a critical regulator that augments islet self-assembly from iPSCs, and it is feasible to utilize natural biomaterials to build tissue cues essential for multicellular tissue production in vitro.
Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
Authors: Stephanie S. Kim, Shili Xu, Jing Cui, Soumya Poddar, Thuc M. Le, Hovhannes Hayrapetyan, Luyi Li, Nanping Wu, Alexandra M. Moore, Lei Zhou, Alice C. Yu, Amanda M. Dann, Irmina A. Elliott, Evan R. Abt, Woosuk Kim, David W. Dawson, Caius G. Radu, Timothy R. Donahue
Journal: Theranostics (2019)

Arginine (Arg) deprivation is a promising therapeutic approach for tumors with low argininosuccinate synthetase 1 (ASS1) expression. However, its efficacy as a single agent therapy needs to be improved as resistance is frequently observed. Methods: A tissue microarray was performed to assess ASS1 expression in surgical specimens of pancreatic ductal adenocarcinoma (PDAC) and its correlation with disease prognosis. An RNA-Seq analysis examined the role of ASS1 in regulating the global gene transcriptome. A high throughput screen of FDA-approved oncology drugs identified synthetic lethality between histone deacetylase (HDAC) inhibitors and Arg deprivation in PDAC cells with low ASS1 expression. We examined HDAC inhibitor panobinostat (PAN) and Arg deprivation in a panel of human PDAC cell lines, in ASS1-high and -knockdown/knockout isogenic models, in both anchorage-dependent and -independent cultures, and in multicellular complex cultures that model the PDAC tumor microenvironment. We examined the effects of combined Arg deprivation and PAN on DNA damage and the protein levels of key DNA repair enzymes. We also evaluated the efficacy of PAN and ADI-PEG20 (an Arg-degrading agent currently in Phase 2 clinical trials) in xenograft models with ASS1-low and -high PDAC tumors. Results: Low ASS1 protein level is a negative prognostic indicator in PDAC. Arg deprivation in ASS1-deficient PDAC cells upregulated asparagine synthetase (ASNS) which redirected aspartate (Asp) from being used for de novo nucleotide biosynthesis, thus causing nucleotide insufficiency and impairing cell cycle S-phase progression. Comprehensively validated, HDAC inhibitors and Arg deprivation showed synthetic lethality in ASS1-low PDAC cells. Mechanistically, combined Arg deprivation and HDAC inhibition triggered degradation of a key DNA repair enzyme C-terminal-binding protein interacting protein (CtIP), resulting in DNA damage and apoptosis. In addition, S-phase-retained ASS1-low PDAC cells (due to Arg deprivation) were also sensitized to DNA damage, thus yielding effective cell death. Compared to single agents, the combination of PAN and ADI-PEG20 showed better efficacy in suppressing ASS1-low PDAC tumor growth in mouse xenograft models. Conclusion: The combination of PAN and ADI-PEG20 is a rational translational therapeutic strategy for treating ASS1-low PDAC tumors through synergistic induction of DNA damage.
Prenatal polyunsaturated fatty acids and child asthma: Effect modification by maternal asthma and child sex
Authors: Maria José Rosa, Terryl J. Hartman, Margaret Adgent, Kourtney Gardner, Tebeb Gebretsadik, Paul E. Moore, Robert L. Davis, Kaja Z. LeWinn, Nicole R. Bush, Frances Tylavsky, Rosalind J. Wright, Kecia N. Carroll
Journal: Journal of Allergy and Clinical Immunology (2019)
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
Authors: Puyuan Xing, Fan Zhang, Guoqiang Wang, Yu Xu, Chengcheng Li, Shouzheng Wang, Yiying Guo, Shangli Cai, Yan Wang, Junling Li
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Deciphering the correlation between immune-related adverse events (irAEs) categorized by organ system class and clinical benefit of immunotherapy is critical for clinical practice. The aim of this study is to investigate the incidence rates of irAEs and their correlations with objective response rate (ORR) in patients with advanced solid tumours treated with nivolumab (NIVO) or nivolumab plus ipilimumab (NIVO+IPI). <h3>Methods</h3> PubMed, Embase and Cochrane library were searched for eligible studies from January 1st, 2000 to May 1st 2019. Published clinical trials on NIVO or NIVO+IPI with reported irAEs were included. Logit transformation of the irAE incidences was applied for the generation of pooled estimate and Pearson correlation coefficient was calculated to evaluate the correlation between irAE and ORR. <h3>Results</h3> 48 clinical trials involving 7936 patients treated with NIVO or NIVO+IPI were included. Compared to NIVO, NIVO+IPI led to more all-grade and grade 3 or higher irAEs categorized by system organ class (<i>P</i> &lt; 0.05). The ORR of NIVO was positively correlated with the incidence rate of skin (r = 0.79, <i>P</i> &lt; 0.001), gastrointestinal (r = 0.56, <i>P</i> = 0.006) and endocrine irAEs (r = 0.44, <i>P</i> = 0.05), but not hepatic, pulmonary and renal irAEs. The ORR of NIVO+IPI was positively correlated with the incidence rate of skin (r = 0.54, <i>P</i> = 0.04), and gastrointestinal irAEs (r = 0.60, <i>P</i> = 0.02), but not endocrine, hepatic, pulmonary and renal irAEs. <h3>Conclusion</h3> This meta-analysis summarizes the incidence rates of irAEs in patients with advanced solid tumours treated with NIVO or NIVO+IPI, and uncovers their correlations with ORR across multiple neoplasms. These findings highlight the potential of irAE to reflect response to NIVO or NIVO+IPI.
Endolyn (CD164) Interacts with CXCR4 and Modulates the CXCL12-Mediated Homing and Migration of Cord Blood CD133+ Hematopoietic Precusor Cells.
Authors: Suzanne M. Watt, Sinead Forde, Brit Jorgensen Tye, Sarah Newey, Maria Roubelakis
Journal: Blood (2006)
Early and Sustained Response to Azacytidine in High-Risk MDS Patients with Monosomy 7 Correlates with Increased Apoptosis and Not CDKN2B Demethylation.
Authors: Kavita K. Raj, Alison M. John, Aloysius Ho, Nicholas Shaun B. Thomas, Ghulam J. Mufti
Journal: Blood (2005)
Imaging-assisted anticancer nanotherapy
Authors: Anshuman Dasgupta, Ilaria Biancacci, Fabian Kiessling, Twan Lammers
Journal: Theranostics (2019)

Cancer nanomedicines are submicrometer-sized formulations designed to improve the biodistribution of anticancer drugs, resulting in less off-target localization, altered toxicity profiles, improved target site accumulation and enhanced efficacy.Together, these beneficial features have resulted in the regulatory approval of about a dozen nanomedicines for the treatment of solid and hematological malignancies.In recent years, significant progress has been made in combining nanomedicines with imaging, to better understand key aspects of the tumor-targeted drug delivery process, and to address the high inter-and intra-individual heterogeneity in the Enhanced Permeability and Retention (EPR) effect.Strategies explored in this regard have included the use of traditional imaging techniques, companion diagnostics and nanotheranostics.Preclinically, integrating imaging in nanomedicine and drug delivery research has enabled the non-invasive and quantitative assessment of nanocarrier biodistribution, target site accumulation and (triggered) drug release.Clinically, imaging has been emerging as a promising tool for patient stratification, which is urgently needed to improve the translation of cancer nanomedicines.We here summarize recent progress in imaging-assisted anticancer nanotherapy and we discuss future strategies to improve the performance of cancer nanomedicines in patients.
Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling.
Authors: Dirk Hose, Jerome Moreaux, Tobias Meissner, Jean-Francois Rossi, Axel Benner, Karene Mahtouk, Anja Seckinger, Christiane Heiss, Michael Hundemer, Thierry Reme, Jens Hillengass, Katja Herde, Uta Bertsch, John DeVos, Sabine Wenisch, Veronique Pantesco, Anna Jauch, Eric Jourdan, Hartmut Goldschmidt, Bernard Klein, Thomas Moehler
Journal: Blood (2007)
No Difference in Survival or Long-Term Disease Outcomes in Palifermin-Treated Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation.
Authors: Ricardo Spielberger, Mary Territo, Simon Durrant, Stephen Nimer, John McCarty, David Hurd, Dietmar Berger, Jeff Aycock, Mon-Gy Chen, Patrick Stiff
Journal: Blood (2007)
Norovirus: hospitals in England close over 1100 beds in past week
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Hospitals in England have closed more than 1100 beds over the past week, almost double the number closed over the same period last year, in an attempt to stop the spread of norovirus.

NHS England has called on people infected with the virus to stay home from school or work for at least 48 hours after symptoms pass, to avoid passing it to others. Patients are being advised to …
Abnormal Expression of the Plasma Cell Differentiation Factor X-Box Protein 1 (Xbp-1) in Waldenstrom’s Macroglobulinemia.
Authors: Lian Xu, Xavier Leleu, Zachary R. Hunter, Daniel D. Santos, Allen W. Ho, Evdoxia Hatjiharissi, Kelly O’Connor, Robert J. Manning, Mariana Chemaly, Andrew R. Branagan, Christopher J. Patterson, Sigitas Verselis, Edward Fox, Kenneth C. Anderson, Steven Treon
Journal: Blood (2005)
Size‐Dependent EPR Effect of Polymeric Nanoparticles on Tumor Targeting
Authors: Homan Kang, Sunghoon Rho, Wesley R. Stiles, Shuang Hu, Yoonji Baek, Do Won Hwang, Satoshi Kashiwagi, Moon Suk Kim, Hak Soo Choi
Journal: Advanced Healthcare Materials (2019)

Passive targeting of large nanoparticles by the enhanced permeability and retention (EPR) effect is a crucial concept for solid tumor targeting in cancer nanomedicine. There is, however, a trade-off between the long-term blood circulation of nanoparticles and their nonspecific background tissue uptake. To define this size-dependent EPR effect, near-infrared fluorophore-conjugated polyethylene glycols (PEG-ZW800s; 1-60 kDa) are designed and their biodistribution, pharmacokinetics, and renal clearance are evaluated in tumor-bearing mice. The targeting efficiency of size-variant PEG-ZW800s is investigated in terms of tumor-to-background ratio (TBR). Interestingly, smaller sized PEGs (≤20 kDa, 12 nm) exhibit significant tumor targeting with minimum to no nonspecific uptakes, while larger sized PEGs (>20 kDa, 13 nm) accumulate highly in major organs, including the lungs, liver, and pancreas. Among those tested, 20 kDa PEG-ZW800 exhibits the highest TBR, while excreting unbound molecules to the urinary bladder. This result lays a foundation for engineering tumor-targeted nanoparticles and therapeutics based on the size-dependent EPR effect.
Rethinking drug design in the artificial intelligence era
Authors: Petra Schneider, W. Patrick Walters, Alleyn T. Plowright, Norman Sieroka, Jennifer Listgarten, Robert A. Goodnow, Jasmin Fisher, Johanna M. Jansen, José S. Duca, Thomas S. Rush, Matthias Zentgraf, John Edward Hill, Elizabeth Krutoholow, Matthias Kohler, Jeff Blaney, Kimito Funatsu, Chris Luebkemann, Gisbert Schneider
Journal: Nature Reviews Drug Discovery (2019)
Role of Activated Platelets in the Homing, Maturation, and Differentiation of Endotheleal Progenitor Cells (EPCs) to Vascular Subendotheleal Matrix.
Authors: Eli I. Lev, Jing-fei Dong, Marcin Bujak, Khatira Aboulfatova, Neal S. Kleiman, David Harris, Zeev Estrov
Journal: Blood (2006)
Recombinant Activated Factor VII (rFVIIa) Dosing and Efficacy in the Treatment of Cranial Hemorrhage in Hemophilia Patients with Inhibitors: An Analysis of the Hemophilia and Thrombosis Research Society Registry (HTRS) (2004–2008).
Authors: Charles T Nakar, David L. Cooper, Donna DiMichele
Journal: Blood (2008)
A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.
Authors: Nikolas von Bubnoff, Darren R. Veach, Heiko van der Kuip, Walter E. Aulitzky, Jana Saenger, Petra Seipel, William G. Bornmann, Christian Peschel, Bayard Clarkson, Justus Duyster
Journal: Blood (2004)
PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo.
Authors: Joseph Negri, Nicholas Mitsiades, Qingwei Deng, Zhaoqin Wen, David C. Geer, Ciaran McMullan, Vassiliki Poulaki, Teru Hideshima, Dharminder Chauhan, Thomas Meyer, Nikhil C. Munshi, Paul G. Richardson, Andrew L. Kung, Kenneth C. Anderson, Constantine S. Mitsiades
Journal: Blood (2005)
Correlation of Genetic Polymorphisms Detected by Geneohm EPLEX™ Electrochemical Platform with Functional Study for Venous Thrombosis.
Authors: Bo Xu, Steven Thompson, Carol Koenigberger, James Pettay, Arkadiy Silbergleit, Tad Kawashima, Kandice Kottke-Marchant, Raymond R. Tubbs
Journal: Blood (2004)
INFLUENCE OF SURGERY FOR ISCHEMIC HEART DISEASE ON EARLY POSTOPERATIVE LEFT VENTRICULAR FUNCTION
Authors: Takashi Fujiwara, Masataka Yamane, Katsumi Motohiro, Ikuo Takahara, Masaki Sato, Yoichi Kinugasa, Akimitsu Kiso, Tatsuki Katsumura
Journal: Circulation (1979)

The pre- and postoperative systolic time intervals, hemodynamics and serum catecholamines were studied in 30 patients with successful myocardial re-vascularization surgery or left ventricular aneurysmectomy and the influence of the surgery on the left ventricular function was evaluated. 1. Significant depression of left ventricular performance was recognized in the group of patients with left ventricular aneurysm as compared to the patients with angina pectoris with or without previous myocardial infarction before the operation. 2. At 2 hours after the operation, significant decrease of ET/PEP, cardiac index and stroke work index and marked elevation of systemic vascular resistance were seen in the group of patients with aortocoronary bypass surgery who had previous myocardial infarction and with left ventricular aneurysmectomy as compared to the group of patients without previous myocardial infarction. 3. At 2 hours after the operation, ET/PEP seemed to reflect the left ventricular stroke work and the depression of the left ventricular function was mainly affected by the elevation of systemic vascular resistance due to the hypersecretion of serum catecholamines. 4. Reduction of systemic vascular resistance by vasodilator brought an improvement of ET/PEP, cardiac index and stroke work index.